<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
--------------
Date of Report (Date of earliest event reported): September 19, 2000
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Massachusetts 000-19319 04-3039129
----------------------- -------------------- -------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
</TABLE>
130 WAVERLY STREET
CAMBRIDGE, MA 02139
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 577-6000
--------------------------------------------------------------------------------
Page 1 of 6 pages
<PAGE>
ITEM 5. OTHER EVENTS.
On September 19, 2000, we publicly disseminated a press release
announcing that the initial purchasers of our private offering of 5%
Convertible Subordinated Notes have exercised in full their $45 million
overallotment option. The information contained in the press release is
incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 Press Release dated September 19, 2000, "Vertex Pharmaceuticals
Announces Exercise of Overallotment by Underwriters - Company Raises
a Total of $345 Million in Offering."
Page 2 of 6 pages
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: September 19, 2000 By: /s/ Thomas G. Auchincloss, Jr.
---------------------------------
Name: Thomas G. Auchincloss, Jr.
Title: Vice President, Finance
Page 3 of 6 pages
<PAGE>
EXHIBIT INDEX
Exhibit Sequential
Number Description Page Number
------- ----------- -----------
99.1 Press Release dated September 19, 5
2000, "Vertex Pharmaceuticals
Announces Exercise of Overallotment
by Underwriters - Company Raises
a Total of $345 Million in Offering."
Page 4 of 6 pages
